Bridging the phenotype-target gap for molecular generation via multi-objective reinforcement learning

2026-04-21 · Source: cs.AI updates on arXiv.org · Field: Health & Wellbeing — Pharmaceuticals & Biotechnology, Artificial Intelligence & Machine Learning, Health & Medical Research · Depth: Expert, long

Summary

ExMolRL is a novel generative framework designed for de novo molecular generation in AI-driven drug design, addressing limitations of existing phenotype-based and target-based strategies. It integrates phenotypic and target-specific cues, utilizing a phenotype-guided generator pretrained on drug-induced transcriptional profiles. This generator is then fine-tuned via multi-objective reinforcement learning (RL). The RL reward function combines docking affinity and drug-likeness scores, enhanced with ranking loss, prior-likelihood regularization, and entropy maximization. This approach guides the model to produce potent, diverse chemotypes aligned with specified phenotypic effects. Extensive experiments show ExMolRL's superior performance over state-of-the-art models across multiple targets, generating molecules with favorable drug-like properties, high target affinity, and inhibitory potency (IC50) against cancer cells.

Key takeaway

For AI Scientists and Research Scientists developing new drug discovery platforms, ExMolRL's integrated framework offers a robust approach to overcome the limitations of purely phenotype- or target-driven methods. You should consider adopting a multi-objective reinforcement learning strategy that combines phenotypic profiles with target protein structures, ensuring generated molecules exhibit both desired cellular effects and high binding affinity, while mitigating reward exploitation through regularization.

Key insights

ExMolRL combines phenotype-guided generation with target-aware reinforcement learning for de novo drug discovery.

Principles

• Integrate phenotypic and target-specific cues for comprehensive drug design.
• Use multi-objective RL to balance potency, diversity, and phenotypic alignment.
• Regularize RL with ranking loss, prior likelihood, and entropy for stability.

Method

ExMolRL pretrains a dual-channel VAE on transcriptional profiles, then fine-tunes it with RL using a reward function that combines docking scores, QED, ranking loss, prior likelihood, and entropy regularization.

In practice

• Pretrain generators on large-scale drug-induced transcriptional profiles.
• Incorporate LeDock scores for binding affinity and RDKit for QED.
• Apply ranking loss to guide RL with fine-grained property feedback.

Topics

• De Novo Molecular Generation
• Multi-Objective Reinforcement Learning
• Phenotype-Guided Drug Design
• Target-Based Drug Discovery
• Drug-Likeness

Best for: AI Scientist, Research Scientist, Machine Learning Engineer

Related on AIssential

• Generalizable mutation-effect prediction across adaptive immune recognition via unified multimodal framework — UniAIR unifies multimodal data and structural information to predict immune mutation effects with high generalizability.
• Contrastive Geometric Learning Unlocks Unified Structure- and Ligand-Based Drug Design — ConGLUDe unifies structure- and ligand-based drug design via contrastive geometric learning, enabling diverse drug discovery tasks.
• CP-Agent: Context-Aware Multimodal Reasoning for Cellular Morphological Profiling under Chemical Perturbations — CP-Agent uses an MLLM and context-aware image-metadata embedding to generate interpretable rationales for drug-induced cell changes.
• From discovery to design: in conversation with Ali Madani (Profluent) — AI-driven language models can design novel, functional proteins from scratch, accelerating biological evolution for therapeutic applications.
• Reinforcement learning-based design of sequential drug treatment targeting the evolving tumour landscape with SequenTx — SequenTx uses reinforcement learning and a virtual cell model to design effective sequential drug treatments for evolving tumors.
• Why We're Not Close to AI Drugs Yet | Isomorphic Labs — Drug design comprises multiple distinct ML problems, not a single one, despite AlphaFold 2's protein structure prediction success.

Open in AIssential →

Editorial summary, takeaway, and curation by AIssential. Original article published by cs.AI updates on arXiv.org.